Target intelligence / Profile preview

NOP53 antisense RNA 1 (NOP53-AS1)

Target
NOP53-AS1
Molecular classification
Long noncoding RNA (lncRNA), Antisense RNA
01

Overview

NOP53 antisense RNA 1 (NOP53-AS1) is a long noncoding antisense RNA transcribed from the opposite strand of the NOP53 gene locus. Members of the antisense lncRNA family, such as NOP53-AS1, typically regulate their sense protein-coding gene (here, NOP53/GLTSCR2) through diverse mechanisms including chromatin remodeling, transcriptional control, mRNA stability, and modulation of translation. Antisense lncRNAs are often involved in cell proliferation, apoptosis, and metastasis, frequently functioning as either tumor suppressors or oncogenes, although specific data for NOP53-AS1 are lacking in the provided literature. Like other antisense lncRNAs, NOP53-AS1 may be differentially expressed in cancer and might play a regulatory role in tumorigenesis, but its clinical significance and functional impacts are not yet well established[2]. If you meant to inquire about the protein-coding gene NOP53 (GLTSCR2), which is a nucleolar protein with tumor suppressor function and is directly involved in p53 signaling and ribosome biogenesis, please clarify, as that is a distinct and better-characterized molecular entity[5].

Other names
GLTSCR2-AS1CTD-2571L23.6GLTSCR2 antisense RNA 1NOP53-AS1
02

Mechanism of action

None directly reported for drugs; possible mechanisms by which modulation could impact disease include regulation of gene transcription, epigenetic modulation, or RNA stability

03

Biological functions

Regulation of gene expression (especially NOP53/GLTSCR2 sense gene)Possible roles in chromatin modification, transcriptional and post-transcriptional regulation, and mRNA stability, by analogy to other antisense RNAs
04

Disease associations

Cancer (by analogy to other antisense lncRNAs, which can act as tumor suppressors or oncogenes depending on context; however, no definitive disease association for NOP53-AS1 itself is documented in the available results)
05

Safety considerations

None described, as there are no drugs or clinical interventions specifically targeting NOP53-AS1
06

Biomarkers

None specifically established; potential as a biomarker analogous to other antisense lncRNAs if expression correlates with disease state

Beyond the preview

Go deeper on NOP53 antisense RNA 1 (NOP53-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOP53 antisense RNA 1 (NOP53-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call